Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 7/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853618 | 0.85 | SLC6A4 (0.51) | CCR2SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL4849548 | 0.82 | OPRL1 (0.51) | CCR2SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL4848483 | 0.82 | SLC6A4 (0.44) | CCR2SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL3133325 | 0.79 | SLC6A4 (0.76) | CCR2SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL4848259 | 0.79 | SLC6A4 (0.52) | CCR2SLC6A4SLC6A3SLC6A2TACR1 | |
| Hydrochloric Acid SCHEMBL4851707 | 0.78 | SLC6A4 (0.74) | SLC6A4SLC6A3SLC6A2TACR1OPRM1 | |
| SCHEMBL4852933 | 0.77 | MAPT (0.47) | TACR1 | |
| SCHEMBL2811089 | 0.75 | TACR1 (0.53) | CCR2SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL5628554 | 0.74 | TACR1 (0.56) | CCR2SLC6A4SLC6A3SLC6A2TACR1 | |
| SCHEMBL6266690 | 0.74 | SLC6A4 (0.51) | CCR2SLC6A4SLC6A3SLC6A2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423039-B2 | (4-phenylpiperazin-1-yl)acylpiperidine derivatives, preparation thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| US-20070021609-A1 | 4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021609-A1 | 4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | AGPAT5, DNPEP, AGPAT2 | CCR2 4001/4885SLC6A4 975/4885SLC6A3 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.